Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
Diabetes Res Clin Pract ; 166: 108303, 2020 Aug.
Article in English | MEDLINE | ID: covidwho-912141

ABSTRACT

The coronavirus disease-2019 (COVID-19) has been designated as a highly contagious infectious disease caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) since December 2019, when an outbreak of pneumonia cases emerged in Wuhan, China. The COVID-19 pandemic has led to a global health crisis, devastating the social, economic and political aspects of life. Many clinicians, health professionals, scientists, organizations, and governments have actively defeated COVID-19 and shared their experiences of the SARS-CoV2. Diabetes is one of the major risk factors for fatal outcomes from COVID-19. Patients with diabetes are vulnerable to infection because of hyperglycemia; impaired immune function; vascular complications; and comorbidities such as hypertension, dyslipidemia, and cardiovascular disease. In addition, angiotensin-converting enzyme 2 (ACE2) is a receptor for SARS-CoV-2 in the human body. Hence, the use of angiotensin-directed medications in patients with diabetes requires attention. The severity and mortality from COVID-19 was significantly higher in patients with diabetes than in those without. Thus, the patients with diabetes should take precautions during the COVID-19 pandemic. Therefore, we review the current knowledge of COVID-19 including the global and regional epidemiology, virology, impact of diabetes on COVID-19, treatment of COVID-19, and standard of care in the management of diabetes during this critical period.


Subject(s)
Betacoronavirus/isolation & purification , Coronavirus Infections/epidemiology , Diabetes Mellitus/physiopathology , Pneumonia, Viral/epidemiology , COVID-19 , Comorbidity , Coronavirus Infections/complications , Coronavirus Infections/virology , Diabetes Mellitus/epidemiology , Diabetes Mellitus/virology , Global Health , Humans , Pandemics , Pneumonia, Viral/complications , Pneumonia, Viral/virology , Republic of Korea/epidemiology , SARS-CoV-2
2.
Diabetes Metab J ; 44(3): 372-381, 2020 06.
Article in English | MEDLINE | ID: covidwho-622859

ABSTRACT

Diabetes has been associated with more severe outcomes and higher mortality in coronavirus disease 2019 (COVID-19) patients compare to morbidity and mortality in patients without diabetes. Several mechanisms may play a role in this greater morbidity and mortality, especially uncontrolled hyperglycemia, an impaired immune system, pre-existing proinflammatory states, multiple comorbidities, and dysregulated angiotensin-converting enzyme 2 signaling. Thus, the diabetes medical community emergently needs to know about COVID-19 and its effects on patients with diabetes, as they must take precautions to carefully manage these patients during the COVID-19 pandemic. The Korean Diabetes Association provides some guidance and practical recommendations for the management of diabetes during the pandemic. This report provides insight into the association between diabetes and COVID-19, proper management of diabetes in patients with COVID-19 and an official suggestion by the Korean Diabetes Association for managing the COVID-19 outbreak.


Subject(s)
Coronavirus Infections/complications , Diabetes Complications/virology , Pneumonia, Viral/complications , COVID-19 , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Disease Management , Humans , Pandemics/prevention & control , Pneumonia, Viral/epidemiology , Pneumonia, Viral/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL